Mylan
Data Breaches, Cyber Attacks and Security Report

Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.Mylan went public on the OTC market in February 1973. It is listed on the NASDAQ, and its shares have been a component of NASDAQ Biotechnology, NASDAQ 100, and the S&P 500 indices.The company develops and produces medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.In 2016, Mylan's pricing of the EpiPen, an epinephrine autoinjector, became controversial and was widely referred to as "price gouging". As a result, investigations were opened into whether Mylan had misclassified the EpiPen under the Medicaid Drug Rebate Program, a common form of pharmaceutical fraud.

Heather Bresch